Compare Novo Nordisk A/S (NVO) vs Sony Group Corp (SONY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Sony Group Corp — how do they compare? Novo Nordisk A/S trades at $49.37 (market cap $220.53B), while Sony Group Corp trades at $21.01 (market cap $125.96B). The key difference: Novo Nordisk A/S is the larger of the two by market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| NVO | SONY | |
|---|---|---|
Market Cap | $220.53B | $125.96B |
Sector | Health | Technology |
52-Week High | $71.70 | $30.26 |
52-Week Low | $35.29 | $19.32 |
Enterprise Value | $239.49B | $122.45B |
Dividend Yield | 3.63% | 0.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $49.38, down 1.87% amid legal action against Eli Lilly over GLP-1 drug advertising. The stock maintains strong fundamentals with a P/E of 11.91 and robust profitability margins (net income margin 37.2%, ROE 71.4%). Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.04 surpassing the $0.87 estimate. Technical indicators show a bullish moving average signal while oscillators remain neutral, with key support at $48.
Outlook remains positive given strong earnings momentum and market leadership in GLP-1 drugs, though legal risks and competitive pressures from Eli Lilly pose near-term headwinds. Analyst consensus is bullish (57.9% buy ratings) with projected revenue growth to $327.8B in 2026. Key risks include litigation outcomes and market share competition in the weight-loss drug segment.
Sony trades at $21.02, down 0.47% on the day. The stock shows a bullish technical signal with strong moving average alignment, though oscillators are neutral. Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026. Revenue for 2025 was $12.96 trillion with a net income of $1.14 trillion, though 2026 projections indicate a net loss. Analyst sentiment is positive with 11 buy ratings and no sell recommendations.
The outlook for Sony is mixed; strong cash flow and a solid balance sheet support growth in entertainment and AI investments, but the shift away from physical media and projected 2026 losses pose risks. Investor sentiment remains cautiously optimistic given the bullish analyst consensus and strategic initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →
